It’s what biopharma CEOs dream of: winning an approval for a drug they’ve helped develop and delivering it to patients. With its PDUFA date slated for Aug. 13, Citius Pharmaceuticals is on that path with Lymphir, an immunotherapy for a rare blood cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,